PharmaCyte Biotech’s CEO Featured Speaker at Marcum MicroCap Conference
May 31 2016 - 9:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that the Chief
Executive Officer of PharmaCyte will be a featured presenter at the
5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in
New York City at the Grand Hyatt Hotel. The presentation is
scheduled to begin at 9:30 a.m. EDT and will be available via a
live webcast. To access the webcast go to
http://wsw.com/webcast/marcum4/pmcb.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said
of the opportunity to speak at the Marcum MicroCap Conference, “We
have a very busy June ahead of us, and it all begins in New York at
Marcum. I couldn’t be more excited to present PharmaCyte’s
remarkable story to a captive audience at this conference. We
expect that many of our shareholders will listen in as well. From
New York we head to Chicago to participate in ASCO 2016, the annual
meeting of the American Society of Clinical Oncology (ASCO) and
then to San Francisco to attend BIO 2016. So in addition to all of
the work in which we are involved in getting our pancreatic cancer
therapy into a Phase 2b clinical trial, we have some exceptional
opportunities to tell what is truly an amazing story about our
therapies that use PharmaCyte’s signature live-cell encapsulation
technology, Cell-in-a-Box®.”
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, lesser known public companies with less than
$500 million in market capitalization. The Marcum MicroCap
Conference is dedicated to providing a forum where these companies
can network with the investment community. The conference features
presentations by CEOs and CFOs from seven principal industry
sectors, expert panels moderated by industry leaders and the
opportunity to meet with management of presenting companies on a
one-on-one basis. The event attracts fund managers and high net
worth investors who focus on small cap equities. Over 2,000
participants of the microcap market participated in last year’s
conference
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This technology will be used as a
platform upon which treatments for several types of cancer and
diabetes are being developed. PharmaCyte’s treatment for cancer
involves encapsulating genetically modified live cells that convert
an inactive chemotherapy drug into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted in a patient, a
chemotherapy drug which needs to be activated in the body
(ifosfamide) is then given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been placed. When the ifosfamide, which
is normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the chemotherapy drug takes
place at the source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting
and advisory services firms in the nation, with offices in major
business markets throughout the U.S., Grand Cayman and China.
Headquartered in New York City, Marcum provides a full spectrum of
traditional tax, accounting and assurance services; advisory,
valuation and litigation support; and an extensive range of
specialty and niche industry practices. Marcum serves both
privately held and publicly traded companies, as well as high net
worth individuals, private equity and hedge funds, with a focus on
middle-market companies and closely held family businesses. In
2015, Marcum’s SEC Services Practice group led all non “Big Four”
accounting firms in the performance of audits in connection with
Initial Public Offerings ("IPOs"). Marcum is a member of the Marcum
Group, an organization providing a comprehensive array of
professional services. For more information, visit
www.marcumllp.com.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate", "believe", "estimate",
"expect", "intend", "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com